-Wall Street Journal
Canaccord Genuity Initiates Coverage On Lucid Diagnostics with Buy Rating, Announces Price Target of $18
Canaccord Genuity analyst Kyle Mikson initiates coverage on Lucid Diagnostics (NASDAQ:LUCD) with a Buy rating and announces Price Target of $18.